Cannabis Bioscience International Holdings (CBIH) Announces Partnership with Stephen Gould for Manufacturing and Distribution of Medical Products
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) has announced a significant partnership with Stephen Gould, a company known for its robust global network and expertise in manufacturing and distribution. This collaboration aims to enhance the delivery of CBIH’s advanced medical product line. Stephen Gould, with over 80 years of experience and operations in more than 40 locations across six countries, brings a wealth of knowledge and a prestigious client portfolio including Walmart, The Children’s Place, GoPro, and Verizon.
According to CBIH’s R&D Director, Rosangel Andrades, this partnership will expedite the market delivery of CBIH's innovative formulations. CBIH will provide its proprietary medical formulations, while Stephen Gould will handle manufacturing and distribution. The first wave of products is expected to launch in the first quarter of 2025.
This partnership is a strategic move for CBIH, aiming to improve market reach and operational efficiency, reaffirming its commitment to delivering quality, science-driven medical solutions.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) ha annunciato una partnership significativa con Stephen Gould, un'azienda nota per la sua solida rete globale e la sua esperienza nella produzione e distribuzione. Questa collaborazione mira a migliorare la consegna della linea di prodotti medici avanzati di CBIH. Stephen Gould, con oltre 80 anni di esperienza e operazioni in più di 40 sedi in sei paesi, porta con sé una grande esperienza e un prestigioso portafoglio clienti che include Walmart, The Children’s Place, GoPro e Verizon.
Secondo il Direttore R&D di CBIH, Rosangel Andrades, questa partnership accelererà la consegna sul mercato delle formulazioni innovative di CBIH. CBIH fornirà le proprie formulazioni mediche proprietarie, mentre Stephen Gould si occuperà della produzione e distribuzione. La prima ondata di prodotti è prevista per il primo trimestre del 2025.
Questa partnership rappresenta una mossa strategica per CBIH, mirata a migliorare la portata sul mercato e l'efficienza operativa, riaffermando il suo impegno a fornire soluzioni mediche di qualità e basate sulla scienza.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) ha anunciado una asociación significativa con Stephen Gould, una empresa conocida por su sólida red global y experiencia en fabricación y distribución. Esta colaboración tiene como objetivo mejorar la entrega de la línea de productos médicos avanzados de CBIH. Stephen Gould, con más de 80 años de experiencia y operaciones en más de 40 lugares en seis países, aporta una gran cantidad de conocimiento y un prestigioso portafolio de clientes que incluye Walmart, The Children’s Place, GoPro y Verizon.
Según la Directora de I+D de CBIH, Rosangel Andrades, esta asociación acelerará la entrega al mercado de las formulaciones innovadoras de CBIH. CBIH proporcionará sus formulaciones médicas patentadas, mientras que Stephen Gould se encargará de la fabricación y distribución. Se espera que la primera oleada de productos se lance en el primer trimestre de 2025.
Esta asociación es un movimiento estratégico para CBIH, con el objetivo de mejorar el alcance del mercado y la eficiencia operativa, reafirmando su compromiso de ofrecer soluciones médicas de calidad basadas en la ciencia.
캘리포니아 바이오사이언스 인터내셔널 홀딩스 (OTCMKTS: CBIH)는 스티븐 굴드와의 중요한 파트너십을 발표했습니다. 스티븐 굴드는 강력한 글로벌 네트워크와 제조 및 유통 전문성으로 알려진 회사입니다. 이 협력은 CBIH의 첨단 의료 제품 라인의 배송을 향상시키기 위한 것입니다. 스티븐 굴드는 80년 이상의 경험과 6개국 40개 이상의 지역에서 운영되는 경험을 가지고 있으며, Walmart, The Children’s Place, GoPro, Verizon 등 명망 있는 고객 포트폴리오를 보유하고 있습니다.
CBIH의 연구개발 이사인 로산젤 안드라데스에 따르면, 이 파트너십은 CBIH의 혁신적인 제형의 시장 출시에 속도를 높일 것입니다. CBIH는 자체 의료 제형을 제공하고, 스티븐 굴드는 제조 및 유통을 처리할 것입니다. 첫 번째 제품군은 2025년 1분기에 출시될 것으로 예상됩니다.
이번 파트너십은 CBIH에게 전략적인 움직임으로, 시장 접근성과 운영 효율성을 개선하는 것을 목표로 하며, 품질과 과학 기반의 의료 솔루션을 제공하겠다는 의지를 재확인합니다.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) a annoncé un partenariat significatif avec Stephen Gould, une entreprise reconnue pour son solide réseau mondial et son expertise en fabrication et distribution. Cette collaboration vise à améliorer la livraison de la gamme de produits médicaux avancés de CBIH. Stephen Gould, avec plus de 80 ans d'expérience et des opérations dans plus de 40 sites répartis dans six pays, apporte une richesse de connaissances ainsi qu'un prestigieux portefeuille de clients comprenant Walmart, The Children’s Place, GoPro et Verizon.
Selon Rosangel Andrades, la Directrice R&D de CBIH, ce partenariat accélérera la livraison sur le marché des formulations innovantes de CBIH. CBIH fournira ses formulations médicales propriétaires, tandis que Stephen Gould s'occupera de la fabrication et de la distribution. La première vague de produits devrait être lancée au premier trimestre 2025.
Ce partenariat représente un mouvement stratégique pour CBIH, visant à améliorer la portée sur le marché et l'efficacité opérationnelle, reafirmant ainsi son engagement à fournir des solutions médicales de qualité et basées sur la science.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) hat eine bedeutende Partnerschaft mit Stephen Gould angekündigt, einem Unternehmen, das für sein robustes globales Netzwerk und Fachwissen in der Herstellung und Distribution bekannt ist. Diese Zusammenarbeit zielt darauf ab, die Lieferung von CBIHs fortschrittlicher medizinischer Produktlinie zu verbessern. Stephen Gould bringt über 80 Jahre Erfahrung und Tätigkeiten in mehr als 40 Standorten in sechs Ländern mit und hat ein umfangreiches Wissen und ein prestigeträchtiges Kundenportfolio, das Walmart, The Children’s Place, GoPro und Verizon umfasst.
Laut der Forschungs- und Entwicklungsdirektorin von CBIH, Rosangel Andrades, wird diese Partnerschaft die Markteinführung von CBIHs innovativen Formulierungen beschleunigen. CBIH wird seine eigenen medizinischen Formulierungen bereitstellen, während Stephen Gould die Herstellung und Verteilung übernimmt. Die erste Produktwelle wird im ersten Quartal 2025 erwartet.
Diese Partnerschaft ist ein strategischer Schritt für CBIH, der darauf abzielt, die Marktreichweite und operative Effizienz zu verbessern und das Engagement für die Bereitstellung qualitativ hochwertiger, wissenschaftlich fundierter medizinischer Lösungen zu bekräftigen.
- Partnership with Stephen Gould, a reputable company with over 80 years of experience.
- Expansion of market reach and operational efficiency.
- First wave of products set to launch in Q1 2025.
- None.
HOUSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is thrilled to announce a groundbreaking partnership with Stephen Gould, marking a monumental step forward in the manufacturing and distribution of CBIH’s advanced medical product line. This collaboration represents a shared commitment to excellence and innovation in the healthcare industry.
Stephen Gould, a company with a remarkable presence in over 40 locations across six countries, brings an extraordinary legacy of expertise to this partnership. Known for its tailored, locally-oriented solutions, Stephen Gould’s robust global network and prestigious client portfolio—including Walmart, The Children’s Place, GoPro, and Verizon—make it the perfect ally in CBIH’s mission to transform lives through science-backed medical products.
“This partnership is a moment of immense pride for CBIH, as it enables us to fast-track the delivery of our innovative formulations to market,” says Rosangel Andrades, CBIH R&D Director.
With over 80 years of experience and a well-deserved reputation as one of the largest distributors in the United States, Stephen Gould embodies the operational excellence and industry reach that aligns perfectly with our vision. Their unparalleled capabilities in logistics, production management, product marketing, fulfillment, design, and inventory control provide the ideal foundation for this collaboration.
Under the agreement, CBIH will contribute its proprietary medical formulations, while Stephen Gould will take the lead in manufacturing and distribution operations. This collaboration is a testament to our dedication to bringing transformative medical products to patients swiftly and efficiently. We are ecstatic to announce that the first wave of products is set to launch in the first quarter of 2025, a milestone that we could not have achieved without the expertise and commitment of our partners at Stephen Gould.
This partnership reaffirms CBIH’s unwavering commitment to delivering quality, science-driven medical solutions. With Stephen Gould’s support, we are confident in our ability to expand our market reach and operational efficiency.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
FAQ
What does the CBIH partnership with Stephen Gould entail?
When will the first products from the CBIH and Stephen Gould partnership be available?
How will the CBIH and Stephen Gould partnership benefit shareholders?
What companies are part of Stephen Gould's client portfolio?
What is the role of Stephen Gould in the CBIH partnership?
What expertise does Stephen Gould bring to the CBIH partnership?
